Literature DB >> 8538747

Sensitization of cells and retroviruses to human serum by (alpha 1-3) galactosyltransferase.

Y Takeuchi1, C D Porter, K M Strahan, A F Preece, K Gustafsson, F L Cosset, R A Weiss, M K Collins.   

Abstract

Mammalian C-type retroviruses are inactivated by human serum, following triggering of the classical complement cascade. This may have inhibited transmission to humans of C-type oncoviruses from other mammals. Indeed, the retroviruses human immunodeficiency virus and human T-cell leukaemia virus are resistant to human complement. Antibody-independent activation of human C1q, the first component of the classical pathway, by retroviral envelope proteins has been described. However, retroviruses produced from human cells are resistant to inactivation by human complement and human serum is known to contain antibodies directed against carbohydrates on retroviral envelopes. Gal(alpha 1-3)Gal terminal carbohydrates are expressed by most mammals but are absent in humans, which lack a functional (alpha 1-3)galactosyltransferase gene. Here, we demonstrate that anti-Gal(alpha 1-3)Gal antibodies in human serum inactivate retroviruses produced from animal cells. Expression of porcine (alpha 1-3)galactosyltransferase in human cells renders the cells and the retroviruses they produce sensitive to human serum.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8538747     DOI: 10.1038/379085a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  46 in total

1.  Chimeric retroviral helper virus and picornavirus IRES sequence to eliminate DNA methylation for improved retroviral packaging cells.

Authors:  W B Young; C J Link
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

2.  Single-step conversion of cells to retrovirus vector producers with herpes simplex virus-Epstein-Barr virus hybrid amplicons.

Authors:  M Sena-Esteves; Y Saeki; S M Camp; E A Chiocca; X O Breakefield
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

3.  Sensitization of rhabdo-, lenti-, and spumaviruses to human serum by galactosyl(alpha1-3)galactosylation.

Authors:  Y Takeuchi; S H Liong; P D Bieniasz; U Jäger; C D Porter; T Friedman; M O McClure; R A Weiss
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

Review 4.  Cross-species virus transmission and the emergence of new epidemic diseases.

Authors:  Colin R Parrish; Edward C Holmes; David M Morens; Eun-Chung Park; Donald S Burke; Charles H Calisher; Catherine A Laughlin; Linda J Saif; Peter Daszak
Journal:  Microbiol Mol Biol Rev       Date:  2008-09       Impact factor: 11.056

Review 5.  Vectors for cancer gene therapy.

Authors:  J Zhang; S J Russell
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

Review 6.  How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?

Authors:  Per Johan Klasse; Rogier W Sanders; Andrea Cerutti; John P Moore
Journal:  AIDS Res Hum Retroviruses       Date:  2011-05-20       Impact factor: 2.205

Review 7.  Gene therapy for rheumatoid arthritis. Theoretical considerations.

Authors:  Y Chernajovsky; A Annenkov; C Herman; K Triantaphyllopoulos; D Gould; H Dreja; S P Moyes; J L Croxford; R A Mageed; O L Podhajcer; D Baker
Journal:  Drugs Aging       Date:  1998-01       Impact factor: 3.923

8.  A new system for stringent, high-titer vesicular stomatitis virus G protein-pseudotyped retrovirus vector induction by introduction of Cre recombinase into stable prepackaging cell lines.

Authors:  T Arai; K Matsumoto; K Saitoh; M Ui; T Ito; M Murakami; Y Kanegae; I Saito; F L Cosset; Y Takeuchi; H Iba
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

9.  A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes.

Authors:  D S Ory; B A Neugeboren; R C Mulligan
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

Review 10.  Extravascular use of drug-eluting beads: a promising approach in compartment-based tumor therapy.

Authors:  Simon Binder; Andrew L Lewis; J-Matthias Löhr; Michael Keese
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.